7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tuning the Antigen Density Requirement for CAR T Cell Activity

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Insufficient reactivity against cells with low antigen density has emerged as an important cause of CAR resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and the CAR construct in axicabtagene-ciloleucel (CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19–4-1BBζ) against antigen low tumors. Enhancing signal strength by including additional ITAMs in the CAR enables recognition of low antigen density cells, while ITAM deletions blunt signal and increase the antigen density threshold. Further, replacement of the CD8 hinge-transmembrane (H/T) region of a 4–1BBζ CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunological synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4–1BBζ-CARs with enhanced capacity to recognize antigen low targets while retaining a superior capacity for persistence.

          Related collections

          Author and article information

          Journal
          101561693
          39259
          Cancer Discov
          Cancer Discov
          Cancer discovery
          2159-8274
          2159-8290
          24 February 2021
          19 March 2020
          May 2020
          08 March 2021
          : 10
          : 5
          : 702-723
          Affiliations
          [1 ]Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
          [2 ]Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
          [3 ]Department of Cellular and Molecular Pharmacology, University of California, San Francisco
          [4 ]Biophysics Program, Stanford University, Stanford, CA
          [5 ]Department of Bioengineering, Stanford University School of Medicine, Stanford, CA
          [6 ]Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
          [7 ]KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
          [8 ]Department of Chemical Engineering, Stanford University, Stanford, CA
          [9 ]Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA
          [10 ]The Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA
          [11 ]Department of Medicine, Stanford University School of Medicine, Stanford, CA
          Author notes

          Author Contributions: RGM, ES, JHM, EWW, ARD, RDV, and CLM designed the research; RGM, SPR, ES, RD, VTV, LL, JHM, MK, EWW, AMT, RMR, SH, SMN, VW, JT, RCL, and PX conducted experiments; RGM, SPR, ES, RD, VTV, JHM, RMR, EWW, and CLM analyzed data; RGM and CLM wrote the manuscript.

          [* ]To whom correspondence should be addressed: Crystal L. Mackall, MD, 265 Campus Dr G3141A, MC5456, Stanford, California 94305, (650) 725-2553, cmackall@ 123456stanford.edu
          Article
          PMC7939454 PMC7939454 7939454 nihpa1578835
          10.1158/2159-8290.CD-19-0945
          7939454
          32193224
          5276b5c8-f004-43e5-9b0e-4b3594031bfa
          History
          Categories
          Article

          Comments

          Comment on this article